Preclinical CRC models and early clinical experiences show that OV + PD-1/PD-L1 increases intratumoral CD8+ T cells, Th1 cytokines, and tumor control, supporting cold-to-hot conversion [68,128]. The gene discussed is CD8A; the disease is neoplasm.